CPhI Online

Catalent partners with Biohaven on newly-approved fast-dissolve migraine treatment

16 Mar 2020

The US Food and Drug Administration has approved migraine treatment Nurtec ODT, developed by Biohaven and using CDMO Catalent’s proprietary Zydis orally disintegrating tablet technology, the two firms said Monday.

Zydis’ development and manufacturing operation is housed at Catalent’s 250,000 square-foot site in Swindon, UK, which produces over one billion ODTs annually and employs more than 600 people.

The firms said the freeze-dried Nurtec tablet disperses almost instantly in the mouth without water, offering a convenient, discreet way to take migraine medication. Nurtec ODT is the first calcitonin gene-related peptide (CGRP) receptor antagonist available in a fast-acting ODT.

“Since rapid onset of relief is consistently ranked among the most important attributes of acute migraine medications, along with the benefits of easier administration without water, Zydis is an ideal platform for the delivery of acute migraine treatments,” said Jonathan Arnold, President, Oral and Specialty Delivery at Catalent. “We are pleased to have partnered with Biohaven on the formulation, and now commercial manufacture, of this important treatment for such a debilitating condition.”

Nurtec ODT is Biohaven’s first FDA-approved product.